AlphAIAlphAI — Financial news for AI agents
investing.com$CRMD

CorMedix reports $355M cash, reaffirms 2026 revenue guidance

CorMedix (CRMD) reported $355M in cash as of September 30 and reaffirmed its 2026 revenue guidance of $325M-$345M. The CMS set a Q1 2027 Add-on payment for DefenCath at $8.32 per session, within the company's guided range. CorMedix expects the Add-on to decline in Q2 2027 but increase in Q3 and Q4, with the average rate exceeding 2x the current rate. The company plans to discuss financial results on November 12, 2026.

Original reporting
investing.com
Published Nov 2, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 1:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CRMD
Neutral
high confidence
Mentioned
$CRMD
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CRMDNeutralMed
01

Why it matters

The cash strength reduces liquidity risk, while steady guidance suggests stable near‑term performance, likely limiting downside pressure.

02

Market read

First disclosure of cash and guidance reaffirmation provides fresh data for traders evaluating CRMD's valuation and risk.

03

What to watch

Potential future CMS payment adjustments could affect long‑term revenue beyond the current guidance.

Relevance 7/10Novelty 7/10Timing: today

Background

CorMedix Therapeutics (NASDAQ:CRMD) is a biopharmaceutical company focused on dialysis‑related therapies. The report includes cash balance and reaffirmed revenue guidance for 2026.

Company-level read

Ticker impact

$CRMDNeutralHigh confidence
Context

CorMedix Therapeutics reported $355M cash and reaffirmed its 2026 revenue guidance of $325M-$345M, a fresh disclosure not previously public.

Expected impact

potential modest upside as investors view the cash cushion and steady guidance favorably

Evidence & confidence

First report of cash balance and guidance reaffirmation; no surprise downgrade, but the data reinforces the company's financial health.

Market effects

Sector

Reaffirmed guidance may bolster confidence in the renal‑therapy biotech sector.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

If the market expected higher guidance, reaffirmation could be seen as a disappointment.

Key entities

  • company
    CorMedix Therapeutics

    Biopharmaceutical firm reporting cash and guidance.

  • regulator
    Centers for Medicare & Medicaid Services (CMS)

    Issued the 2027 End‑Stage Renal Disease payment rule referenced in the report.

Read at source← All news

StoryCMS sets $8.32 DefenCath add‑on for Q1 2027; CorMedix reaffirms 2026 revenue guidance and reports $355 M cash

Also covered by

2 outlets

Related articles

$CRMDMedAI 8/10

CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position Parsippany, NJ – November 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call ex

SEC EDGAR 8-K
$CRMDMed

A federal rule sets an $8.32 add-on payment per DefenCath dialysis session in Q1 2027.

CorMedix Therapeutics (CRMD) reported $355M in cash reserves as of Q3 2026 and reaffirmed its 2026 revenue guidance of $325M-$345M. CMS set an $8.32 Add-on payment per DefenCath dialysis session for Q1 2027, within CorMedix's guided range. The company expects the Add-on to decline in Q2 2027 but increase in later quarters, with an average rate exceeding 2x the current $2.37. CorMedix will discuss its Q3 financial results on November 12, 2026.

stocktitan.net
$CRMDMedAI 8/10

CorMedix Gains FDA Priority Review For REZZAYO's Potential New Indication

CorMedix (CRMD) and Mundipharma's REZZAYO (rezafungin) received FDA Priority Review for preventing invasive fungal diseases. The sNDA is based on the Phase 3 ReSPECT study, with a target action date in Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis. If approved, CorMedix plans to start promotions in H2 2027. CRMD stock is up 0.55% in pre-market trading.

rttnews.com
$CRMDMedAI 8/10

CorMedix Wins Priority Review For REZZAYO SNDA In Fungal Disease Prevention

CorMedix (CRMD) announced the FDA accepted its sNDA for REZZAYO (rezafungin) to prevent fungal diseases, granting Priority Review. The application, submitted by partner Mundipharma, is based on a Phase 3 trial. The FDA set a target action date for Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis in certain patients. The stock was up 0.55% in pre-market trading.

rttnews.com